Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. | Zhu et al. Respiratory Research 2010 11 34 http content 11 1 34 RESPIRATORY RESEARCH RESEARCH Open Access A prostacyclin analogue iloprost protects from bleomycin-induced pulmonary fibrosis in mice 1 1 2 3 1 4 2 1 Yuanjue Zhu Yong Liu Weixun Zhou Ruolan Xiang Lei Jiang Kewu Huang Yu Xiao Zijian Guo Jinming Gao1 Abstract Background Metabolites of arachidonic acid such as prostacyclin PGI2 have been shown to participate in the pathogenesis of pulmonary fibrosis by inhibiting the expression of pro-inflammatory and pro-fibrotic mediators. In this investigation we examined whether iloprost a stable PGI2 analogue could prevent bleomycin-induced pulmonary inflammation and fibrosis in a mouse model. Methods Mice received a single intratracheal injection of bleomycin with or without intraperitoneal iloprost. Pulmonary inflammation and fibrosis were analysed by histological evaluation cellular composition of bronchoalveolar lavage BAL fluid and hydroxyproline content. Lung mechanics were measured. We also analysed the expression of inflammatory mediators in BAL fluid and lung tissue. Results Administration of iloprost significantly improved survival rate and reduced weight loss in the mice induced by bleomycin. The severe inflammatory response and fibrotic changes were significantly attenuated in the mice treated with iloprost as shown by reduction in infiltration of inflammatory cells into the airways and pulmonary parenchyma diminution in interstitial collagen deposition and lung hydroxyproline content. Iloprost significantly improved lung static compliance and tissue elastance. It increased the expression of IFNg and CXCL10 in lung tissue measured by RT-PCR and their levels in BAL fluid as measured by ELISA. Levels ofTNFa IL-6 and TGFP1 were lowered by iloprost. Conclusions Iloprost prevents bleomycin-induced pulmonary fibrosis possibly by upregulating antifibrotic mediators IFNg and CXCL10 and downregulating pro-inflammatory and pro-fibrotic .
